Gastrointestinal Cancer | Topics

 
Abstracts From the 18th Annual Meeting of the International Society of Gastrointestinal Oncology
November 17, 2021

The International Society of Gastrointestinal Oncology (ISGIO), hosted by Physicians’ Education Resource, LLC (PER®) presented the latest advances in the field of gastrointestinal cancer research.

FDA Grants Fast Track Designation to TT-00420 for Cholangiocarcinoma
November 03, 2021

Patients with cholangiocarcinoma may derive benefit from treatment with TT-00420, which was recently given a fast track designation by the FDA.

Survival Unaffected From Addition of Ramucirumab or Merestinib to Standard First-Line Chemotherapy for Metastatic Biliary Tract Cancer
November 01, 2021

Patients with locally advanced or metastatic biliary tract cancer who received either ramucirumab or merestinib in addition to standard first-line cisplatin and gemcitabine did not experience further survival benefit, although safety remained tolerable.

First-Line Durvalumab/Chemotherapy Combo Results in Meaningful Survival Benefit in Advanced Biliary Tract Cancer
October 26, 2021

Patients with advanced biliary tract cancer received a clinically meaningful and statistically significant overall survival benefit after being treated with durvalumab and chemotherapy.

Durvalumab Plus Tremelimumab Combo Provides Significant Survival Benefit in First-Line Unresectable Hepatocellular Carcinoma
October 15, 2021

Patients with unresectable hepatocellular carcinoma appeared to benefit from treatment with durvalumab and tremelimumab, according to findings from the phase 3 HIMALAYA trial.

Biologics License Applications Accepted for Nivolumab/Ipilimumab and Nivolumab/Chemo for Unresectable Advanced ESCC
October 04, 2021

Treatment with nivolumab/ipilimumab and nivolumab/chemotherapy has demonstrated efficacy in unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, with results from the CheckMate-648 trial leading to the acceptance of the regimens’ applications by the FDA.

Overall Survival Favorable With Ivosidenib for Advanced Cholangiocarcinoma With IDH1 Mutations
September 30, 2021

A final overall survival analysis found improved results and a tolerable safety profile for patients with advanced IDH1-mutated cholangiocarcinoma who received ivosidenib vs placebo.

Pembrolizumab Meets Primary End Point of OS in Advanced Pretreat Hepatocellular Carcinoma
September 28, 2021

Patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib appear to benefit from treatment with pembrolizumab and best supportive care.

The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”
September 22, 2021

Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.

Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21, 2021

Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.